On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.
Kelly Chibale describes the drug discovery process as a fairy-tale quest, stating, 'It doesn't mean that there aren't surprises or miracles. They do happen, but you have to kiss many frogs before you meet the prince.' This metaphor illustrates the challenges and unpredictability in finding effective medicines.
I am open-minded; I believe in integrative practices, and I agree that the medical establishment can be arrogant and unduly influenced by the pharmaceutical industry, which now funds so much of medical research. But I fully understand Scherer's frustration with his interminable discussions with Kennedy about scientific articles.
Each day, they pore over reams of data about how the virus is evolving worldwide, how well last year's shot performed, and which strains might be easiest to mass produce for a vaccine. The meeting, convened by the World Health Organization twice a year, is a critical moment for the WHO's Global Influenza Surveillance and Response System.
At the end of January, Washington, DC, saw an extremely unusual event. The MAHA Institute, which was set up to advocate for some of the most profoundly unscientific ideas of our time, hosted leaders of the best-funded scientific organization on the planet, the National Institutes of Health. Instead of a hostile reception, however, Jay Bhattacharya, the head of the NIH, was greeted as a hero by the audience, receiving a partial standing ovation when he rose to speak.
The news is the latest sign of the FDA's heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., particularly those using mRNA technology, which he has criticized before and after becoming the nation's top health official. Moderna received what's called a "refusal-to-file" letter from the FDA that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.
Laboratories turned to a smart workaround when COVID‑19 testing kits became scarce in 2020. They mixed samples from several patients and ran a single test. If the test came back negative, everyone in it was cleared at once. If it was positive, follow-up tests would zero in on who was infected. That strategy, known as group testing, saved valuable time, money, and resources.
While the move came as a surprise to the high-profile vaccine maker, it is just the latest hostility toward vaccines-and mRNA vaccines in particular-from an agency overseen by the fervent anti-vaccine activist Robert F. Kennedy Jr. In his first year in office, Kennedy has already dramatically slashed childhood vaccine recommendations and canceled $500 million in research funding for mRNA vaccines against potential pandemic threats.
Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.
It's clear that the worst is far from over for the NHS this winter, with hospitals again experiencing a rise in patients admitted with flu and other respiratory virus cases last week.
Perhaps the most significant milestone was the adoption by WHO Member States of the Pandemic Agreement, a landmark step towards making the world safer from future pandemics. Alongside this, amendments to the International Health Regulations came into force, including a new pandemic emergency alert level designed to trigger stronger global cooperation. And to sustainably finance the WHO's work, governments in a historic show of support increased their contributions to our core budget.
If you feel like everyone you know is dealing with a cough, cold and runny nose, it's not in your head. Multiple viruses, not just the flu, are currently circulating near season-high levels in the San Francisco Bay Area, according to wastewater data. Flu tests show seasonal influenza activity continues to be elevated in the region, although it's down from the season-high peak at the end of December, according to the California Department of Public Health.
